PG-102
Product Status
- Phase 2a completed
Lead Indications
-
Type 2 diabetes
-
Obesity
-
MASH
Technology
-
NTIG®-engineered GLP-1/GLP-2 biologic
Target Profile
- Monthly injectable
PG-102 is a first-in-class gut-targeted metabolic biologic designed to move treatment beyond conventional incretin paradigms.
By integrating long-acting GLP-1 activity with the complementary biology of GLP-2 co-agonism, PG-102 is being developed to deliver durable metabolic efficacy with improved metabolic quality, enhanced tolerability, and long-term treatment sustainability.
Unlike conventional CNS-driven approaches focused primarily on appetite suppression, PG-102 aims to restore healthier body composition, improve gastrointestinal tolerability, and reduce the chronic metabolic burden associated with obesity and type 2 diabetes.
The program is advancing into multiple Phase 2b studies focused on monthly maintenance therapy, high-exposure obesity regimens, and metabolically vulnerable populations, including elderly type 2 diabetes.
